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ABSTRACT 
Objective: This study evaluated the efficacy of thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke patients within 6 h of 
stroke onset.  
Methods: This cross-sectional study collected data of patients with ischemic stroke received intravenous thrombolytic therapy with 0.6 mg/kg 
alteplase within 6 h of onset in Cipto Mangunkusumo General Hospital (Rumah Sakit Cipto Mangunkusumo [RSCM]) between November 2014 and 
August 2017. Efficacy of the thrombolytic therapy was evaluated using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin 
Scale (mRS). NIHSS evaluated on 24 h and 7 d post thrombolytic therapy portrayed clinical outcomes of patients while mRS evaluated on day 30 
post-thrombolysis portrayed the functional outcome of patients.  
Results: The median NIHSS score decreased on 24 h and 7 d post-thrombolysis. 33.3% patients experienced a reduction of NIHSS score ≥4 on 24 h 
post thrombolytic therapy. On day 7 following thrombolysis, 57.4% patients had a good clinical outcome. On day 30 follow-up, 55.6% patients had a 
good functional outcome. 
Conclusion: Thrombolysis using 0.6 mg/kg intravenous alteplase within 6 h of onset is effective for acute ischemic stroke patients. 
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Stroke is a serious problem in Asia with mortality rate higher than in 
Europe or North America [1]. Two-third of total mortality caused by 
stroke in the world happened in Asia [2]. Stroke can also cause 
permanent or long-term disability [3, 4]. Ischemic stroke is the most 
common type of stroke in the world with a prevalence of 87% [5]. In 
Indonesia, stroke causes the highest mortality from non-communicable 
disease group with ischemia as the main etiology. Prevalence of stroke in 
Indonesia increased from 8.3/1000 population in 2007 to 12.1/1000 
population in 2013 [6]. In 2018, the prevalence of stroke decreased to 
10.9/1000 population [7]. Prevalence of stroke increased with age [6, 7]. 
Stroke is the leading etiology of death and disability [4]. 
Ischemic stroke is caused either by an embolus, thrombus, or systemic 
hypoperfusion. These conditions cause sudden loss of blood 
circulation to the brain, spinal cord, or retina. In the brain, ischemia 
will create irreversible death core zone surrounded by hypoperfusion 
zone called penumbra, which still can be saved [8]. Penumbra can be 
salvaged with reperfusion therapy. Reperfusion therapy can return 
blood circulation to the ischemic penumbra either by injection of 
thrombolytic drugs or removal of the thrombus via thrombectomy. 
National Institute of Neurological Disorders and Stroke (NINDS) 
organized recombinant tissue plasminogen activator (r-TPA) stroke 
study in 1995 which demonstrated that intravenous alteplase therapy 
within 3 h of stroke onset improved functional outcome. Since then, 
this treatment has been approved as recommended first-line therapy 
for patients with acute ischemic stroke by most national and 
international guidelines. In Japan Alteplase Clinical Trial (J-ACT) 
conducted from April 2002 to September 2003, low-dose alteplase 0.6 
mg/kg was selected based on previous r-TPA studies for Japanese 
patients which suggested that 20 MIU of duteplase–r-TPA similar to 
alteplase, was non-inferior than 30 MIU towards partial recanalization 
and complete recanalization. Therefore, 0.6 mg/kg of alteplase–which 
was equivalent to 20 MIU per person or 0.33 MIU/kg at a mean body 
weight 60 kg, was considered as the optimal dose for J-ACT [9]. 
Enhanced Control of Hypertension and Thrombolysis Stroke Study 
(ENCHANTED) involving predominantly Asian patients with acute 
ischemic stroke also showed that the low-dose alteplase was non-
inferior to the standard dose (0.9 mg/kg) [10].  
Despite stroke having high prevalence in the world, especially in Asia, 
the popularity of thrombolytic therapy in developing countries is still 
low. Thrombolytic therapy rate in Indonesia is not available yet. In 
Indonesia, most thrombolytic therapies were done in Cipto 
Mangunkusumo General Hospital (Rumah Sakit Cipto Mangunkusumo 
[RSCM]) as the referral center. Therefore, this study indirectly can 
represent the situation of thrombolytic therapy in Indonesia. Cipto 
Mangunkusumo General Hospital has performed thrombolytic therapy 
since 2014 using 0.6 mg/kg alteplase with onset-to-therapy time up to 6 
h. The purpose of these regulations is to gain the best benefits of 
thrombolytic therapy with minimum therapeutically effective dose 
required and longest onset-to-therapy time allowed. 
Outcome of the thrombolytic therapy on stroke patients can be 
evaluated using the National Institutes of Health Stroke Scale 
(NIHSS) and modified Rankin Scale (mRS). NIHSS evaluates 
impairment of the patient while mRS evaluates disability of the 
patient. NIHSS can be used to measure severity of symptoms related 
with brain infarction and to evaluate post-stroke neurologic deficit. 
NIHSS score can range between 0-42. Higher score represents more 
severe impairment [11]. mRS measures patient’s independency 
post-stroke. mRS score consists of 0 (no symptoms) to 6 (dead) [12].  
The aim of this study was to investigate the efficacy of 0.6 mg/kg 
intravenous alteplase injected on acute ischemic stroke patients 
within 6 h of stroke onset using NIHSS and mRS evaluation.  
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MATERIALS AND METHODS 
Subjects and procedures 
In this cross-sectional study, the patient’s data were obtained from 
the medical records. The subjects in this study were adult acute 
ischemic stroke patients admitted to the Cipto Mangunkusumo 
General Hospital between November 2014 and August 2017 
undergoing intravenous thrombolytic therapy with 0.6 mg/kg 
alteplase within 6 h of stroke onset. Diagnosis of ischemic stroke 
was confirmed by cerebral computed tomography examination. 
Patients with posterior circulation infarct (POCI) or underwent 
intra-arterial therapy (IAT) or mechanical thrombectomy were 
excluded from this study. Patients receiving a dose of alteplase other 
than 0.6 mg/kg or having thrombolytic therapy interrupted due to 
bleeding or allergic reaction were also excluded from this study. 
Factors could potentially influence the outcome of the therapy (e. g. 
dehydration, infection, etc.) had been evaluated and treated based 
on applied guidelines. 
Demographic, clinical, and laboratory data of patients, including 
National Institutes of Health Stroke Scale (NIHSS) score pre-
thrombolysis, NIHSS 24-hours post-thrombolysis score, and NIHSS 
7-days post-thrombolysis score, were collected from the medical 
records. On day 90 post-thrombolysis, the functional outcome of the 
patient was evaluated using modified Rankin Scale (mRS) at the time 
of the outpatient visit or by phone. NIHSS evaluation at 24 h and 7 d 
after thrombolytic therapy were indicators of the patient’s clinical 
outcome. Clinical outcome and functional outcome were indicators 
of efficacy evaluation of thrombolytic therapy using 0.6 mg/kg 
alteplase within 6 h of stroke onset in this study. 
Reduction of NIHSS score before thrombolysis as much as four or 
more on 24 h and/or 7 d after thrombolytic therapy was categorized 
as the good clinical outcome. Score 0-2 of mRS on day 90 post-
thrombolysis were categorized as the good functional outcome 
while score 3-6 were categorized as the poor functional outcome. 
This study also evaluated the possibility of non-modifiable and 
modifiable cerebrovascular risk factors affecting the outcomes of the 
therapy. Non-modifiable risk factors consisted of age and sex while 
modifiable risk factors consisted of hypertension, diabetes mellitus, 
smoking, using antiplatelet and/or anticoagulant agents, atrial 
fibrillation, and previous stroke history.  
Statistical analysis 
Numerical data in this study were presented as means and standard 
deviation if normally distributed, and as median and range if not 
normally distributed. Categorical data were presented as 
frequencies and percentages. Statistical analysis was performed 
using SPSS version 20. Normality of numerical data was tested using 
the Kolmogorov-Smirnov normality test due to the number of 
subject >50. Independent t-test or Mann-Whitney U-test was used to 
compare means in numerical data while chi-square test or Fisher’s 
exact test was used to compare percentages in categorical data. 
RESULTS 
There were 646 stroke patients treated in Cipto Mangunkusumo 
General Hospital between November 2014 and August 2017. Most 
stroke was ischemic stroke (65%; n=420). 73 ischemic stroke 
patients (17.4%) received thrombolytic therapy. Thrombolytic 
therapy on two patients was stopped due to hematemesis and 
allergic reaction. One patient received thrombolytic therapy more 
than 6 h of stroke onset. Eight patients were given a dose of 
alteplase other than 0.6 mg/kg. Intravenous thrombolysis on two 
patients was continued with intra-arterial thrombolysis and on five 
patients was continued with thrombectomy. In total, there were 54 
patients met the inclusion criteria of this study (fig. 1). 
 
 
Fig. 1: Flow chart showing the selection of patients 
 
Almost half of the patients (42.6%) aged ≥6 0 y old. The mean and 
standard deviation for age was 56±11.71 y old. Of all patients, 51.9% 
were women, 22.2% had smoking history or were current smokers, 
27.8% using antiplatelet agents just before the stroke, 3.7% using 
oral anticoagulant agents or anticoagulant injection just before the 
stroke, 68.5% were hypertensive, 31.5% had diabetes mellitus, 
20.4% had atrial fibrillation showed on electrocardiography, 53.7% 
had heart disease (coronary artery disease [CAD] or chronic heart 
failure [CHF] or both), and 22.2% had previous stroke history. Most 
patients (51.9%) had involvement of the left hemisphere–which 
associated with aphasia and functional dependency. Only 9.3% 
patients received thrombolytic therapy before 3 h of stroke onset 
while 90.7% patients received thrombolytic therapy between 3-6 h 
of stroke onset. Table 1 shows baseline characteristics in 54 
patients. Percentage of modifiable risk factors in patients is showed 
in fig. 2. 
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Table 1: Baseline demographic and clinical characteristics of patients 
Variable n % 
Age, y 
<60 31 57.4 
≥60 23 42.6 
Sex 
Male 26 48.1 
Female 28 51.9 
Previous stroke history 
Yes 12 22.2 
No 42 77.8 
Using antiplatelet agents 
Yes 15 27.8 
No 39 72.2 
Using anticoagulant agents 
Yes 2 3.7 
No 52 96.3 
Hemisphere lesion 
Left 28 51.9 
Right 26 48.1 
Stroke subtype 
TACI 17 31.5 
PACI 26 48.1 
LACI 11 20.4 
Onset-to-therapy time, h 
<3 5 9.3 
3-6 49 90.7 
TACI: total anterior circulation infarct, PACI: partial anterior circulation infarct, LACI: lacunar infarct 
 
 
Fig. 2: Percentage of cerebrovascular modifiable risk factors in patients 
 
 
Fig. 3: Line chart showing a decrease of NIHSS median from pre-thrombolysis to 24 h and 7 d post-thrombolysis 
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Outcomes of patients 
Median National Institutes of Health Stroke Scale (NIHSS) 
score of patients before thrombolysis was 10 (range 4-16). The 
median decreased on 24 h and 7 d after thrombolytic therapy; 
7 (range 2-42) and 4.5 (range 0-42), respectively (fig. 3). 
Reduction of NIHSS scores as much as four or more from the 
pre-thrombolysis score was experienced by 33.3% patients 
within 24 h and by 57.4% patients within 7 d following 
thrombolytic therapy (table 2). 
 
Table 2: Clinical and functional outcomes of patients post thrombolytic therapy 
 n % 
Clinical outcome 
On 24 h post-thrombolysis 
Good 18 33.3 
Poor 36 66.7 
On 7 d post-thrombolysis 
Good 31 57.4 
Poor 23 42.6 
Functional outcome 
mRS on day 90 
Good 30 55.6 
Poor 24 44.4 
mRS: modified Rankin Scale.,  
 
 
Fig. 4: Modified rankin scale (mRS) score at 3 mo 
 
On the 90-days follow-up, 55.6% patients had good functional outcome 
with modified Rankin Scale (mRS) scored 0-2. There were 31.5% 
patients had mRS scored 1 and 22.2% patients had score 0, as described 
in fig. 4. Pre-thrombolysis NIHSS score was categorized as <10 and ≥10 
based on its median. From statistical analysis performed, NIHSS score of 
patient before thrombolytic therapy affected clinical outcome on 24 h 
post-thrombolysis (odds ratio [OR]=0.182; 95% confidence interval [CI]: 
0.050-0.666; p=0.007). Pre-thrombolysis NIHSS score of patient also 
statistically affected the functional outcome on day 90 follow-up 
(OR=6.000; 95% CI: 1.815-19.837; p=0.002). 
Correlation between risk factors and outcomes 
Smoking statistically affected the clinical outcome of patients on day 7 
post-thrombolysis (OR=0.200; 95% CI: 0.039-1.025; p=0.039). 
Previous stroke history statistically affected the clinical outcome of 
patients on 24 h post thrombolytic therapy (OR=7.480; 95% CI: 0.882-
63.438; p=0.035). Sex, age, antiplatelet and anticoagulant use, 
hypertension, diabetes mellitus, and atrial fibrillation did not influence 
the outcomes of the thrombolytic therapy statistically. 
DISCUSSION 
There was a balanced proportion between men and women in this 
study. The percentage of woman was 51.9%, and the percentage of 
man was 49.1%. These findings correspond with Riset Kesehatan 
Dasar (RISKESDAS) or basic health research in 2013. RISKESDAS 
2013 stated that there was no imbalance prevalence of stroke 
between men and women in Indonesia [6]. The percentage of female 
patients in this study also resembled the result of the Third 
International Stroke Trial (IST-3) revealing that 52% of patients 
undergoing thrombolytic therapy were women [13].  
Mean age of patients in this study was 55.6±11.7 y old. 42.6% 
patients aged ≥60 y old. These findings correspond with RISKESDAS 
stating that the highest prevalence of stroke was in the population 
aged ≥75 y old and stroke prevalence increased with age [6, 7]. The 
IST-3 was seeking efficacy of intravenous 0.9 mg/kg alteplase within 
6 h of stroke onset in elderly patients. In IST-3 study, majority of the 
patients were older than 80 y old (53%) [13].  
Mean systolic blood pressure of patients on the first-time 
measurement was 150.43±29.96 mmHg–similar with Japan 
Alteplase Clinical Trial (J-ACT) and National Institute of Neurological 
Disorders and Stroke (NINDS) 2 study; 151.0±19.0 mmHg and 
153±22 mmHg, respectively [9]. This result shows that blood 
pressure control–with routine consumption of antihypertensive 
drugs, in Indonesia had been decent. 
Percentage of the antiplatelet user and the anticoagulant user in this 
study was 21.8% and 3.7%, respectively. In Enhanced Control of 
Hypertension and Thrombolysis Stroke Study (ENCHANTED), the 
percentage of the antiplatelet user and the anticoagulant user of 
patients receiving 0.9 mg/kg alteplase was 21.1% and 2.1%, 
respectively, and of patients receiving 0.6 mg/kg alteplase was 24.7% 
and 2.9%, respectively. The percentage of the anticoagulant user in 
this study was slightly higher than ENCHANTED study most likely due 
to the higher percentage of the patient with atrial fibrillation in this 
study (53.7%). In ENCHANTED study, percentage of patient with atrial 
fibrillation was 20.1% (patients receiving 0.9 mg/kg alteplase group) 
and 18.7% (patients receiving 0.6 mg/kg alteplase group) [10].  
Mean blood glucose level of patients measured by stick test was 
160.07±99.11 mg/dl (~8.8 mmol/l). The mean blood glucose level in 
this study was higher than J-ACT study (141.3±48.3 mg/dl) [9]. It was 
also higher than NINDS 2 study and Safe Implementation of 
Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) [9, 14]. These 
findings show that blood glucose control in Indonesia was still lacking. 
Most patients had left hemisphere lesion with partial anterior 
circulation infarct (PACI) as the most common subtype (48.1%), 
followed by total anterior circulation infarct (TACI) 31.5% and 
lacunar infarct (LACI) 20.4%. In IST-3, TACI was the most common 
subtype (42%), followed by PACI (39%) and LACI (11%) [15]. There 
was a bigger involvement of larger blood vessel that associated with 
more severe stroke in IST-3 study than in this study. 
Mean onset-to-therapy or onset-to-needle time of thrombolytic 
therapy in this study was 279.26±91.73 min (~4 h 39 min), and 
most patients (53.7%) received thrombolytic therapy within 4.5-6 h 
since onset. In J-ACT study, the mean onset-to-therapy time was 
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shorter than this study (150.5±119.7 min) because J-ACT set the 
onset-to-therapy time only up to 3 h [9]. IST-3 study set the onset-
to-therapy time up to 4.5 h; most patients received thrombolytic 
therapy within 3-4.5 h [14].  
Modifiable risk factors of cerebrovascular disease having the highest 
percentage in this study were hypertension (68.5%), heart disease 
(53.7%), and diabetes mellitus (31.5%). These results correspond with 
the result of the ENCHANTED study. In ENCHANTED study, 
hypertension had the highest percentage in both the low-dose alteplase 
group and the standard-dose alteplase group (62.6% and 63.0%, 
respectively). Chi-square test was performed to analyze the correlation 
between cerebrovascular risk factors and outcomes of thrombolytic 
therapy. Smoking was statistically proven affecting the clinical outcome 
of patients on day 7 post thrombolytic therapy (OR=0.200; 95% CI: 
0.039-1.025; p=0.039). This result corresponds with ENCHANTED study 
revealing that smoking had the second-highest percentage as one of the 
modifiable risk factors in cerebrovascular diseases [10].  
National Institutes of Health Stroke Scale (NIHSS) evaluation on 24 h 
post thrombolytic therapy was appointed as the primary outcome in 
NINDS and J-ACT study while modified Rankin Scale (mRS) evaluation 
on follow-up day 90 was the secondary outcome [9]. In this study, the 
functional outcome of patients was measured by mRS evaluated on 
day 90 post thrombolytic therapy, and clinical outcome was measured 
by NIHSS evaluated on 24 h and 7 d post-thrombolysis. NIHSS score 
reduction ≥4 from the pre-thrombolysis NIHSS score was experienced 
by 33.3% patients within 24 h and by 57.4% patients within 7 d 
following the thrombolytic therapy. Percentage of patients 
experiencing ≥4 NIHSS score reduction on 24 h post-thrombolysis in 
this study was lower than J-ACT study, which was 49.5%. This gap is 
probably due to the different length of onset-to-therapy time set in J-
ACT and this study. In J-ACT study, the onset-to-therapy time was only 
up to 3 h. In this study, only 9.3% patients received thrombolytic 
therapy before 3 h of stroke onset while 90.7% patients received 
thrombolytic therapy between 3-6 h of onset. After three months, 
55.6% patients had a good functional outcome with mRS scored 0-2. 
According to Safe Implementation of Treatments in Stroke (SITS) 
Thrombolysis Registry, score 0-2 on mRS day 90 post-thrombolysis 
portrayed functional independency–which happened on 55.4% 
subjects [16]. These findings show that longer onset-to-therapy time 
was associated with more variable clinical outcome. However, onset-
to-therapy time did not affect the patient’s functional independence.  
The length of onset-to-therapy time in ENCHANTED study was up to 
4.5 h. In ENCHANTED study, the thrombolytic therapy was considered 
delivering good outcome if the mRS scored 0 or 1. mRS score 0 and 1 
was owned by 25.1% and 21.7% patients in the low-dose group, 
respectively, and by 24.8% and 24.1% patients in the standard-dose 
group, respectively [10]. In this study, mRS score 0 was found in 
22.2% patients and score 1 was found in 31.5% patients. This result 
shows that outcomes of thrombolytic therapy injected ≤6 h was non-
inferior to thrombolytic therapy injected ≤4.5 h.  
Based on statistical analysis performed in this study, NIHSS score 
pre-thrombolysis affected the clinical outcome on 24 h post 
thrombolytic therapy and the functional outcome measured on day 
90 follow-up of the patient. These findings show that higher NIHSS 
score before thrombolytic therapy was correlated with more severe 
stroke–wider brain tissue damage and more extensive involvement 
of blood vessels, thus resulting in poorer outcomes of the patient. 
This study used a cross-sectional method which only could 
represent a one-time condition. Confounding factors potentially 
influencing the outcome of the patients could not be controlled. This 
study also used a consecutive sampling method so that the samples 
were not normally distributed. Another limitation of this study was 
mRS on day 90 post-thrombolysis was collected through recall 
memory on some of the patients. However, the possibility of error 
was reduced with rechecking on the medical record data. 
CONCLUSION 
Results of this study suggest that thrombolysis with 0.6 mg/kg 
intravenous alteplase was non-inferior to those with 0.9 mg/kg 
intravenous alteplase used in Europe and North America. 
Thrombolytic therapy given within 6 h of onset was non-inferior to 
thrombolytic therapy injected ≤4.5 h although thrombolysis injected 
≤3 h gave a more favorable outcome. In conclusion, thrombolysis 
with 0.6 mg/kg intravenous alteplase within 6 h of onset is effective 
for acute ischemic stroke patients.  
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